Krystal Biotech (KRYS) Operating Leases (2019 - 2026)

Krystal Biotech (KRYS) has 8 years of Operating Leases data on file, last reported at $7.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 11.9% year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2026 stood at $7.3 million (down 11.9% YoY), and the FY2025 full-year result was $7.6 million, up 25.22% from the prior year.
• Operating Leases declined to $7.3 million in Q1 2026, from $7.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $9.7 million in Q2 2025 to a low of $6.0 million in Q4 2024.
• A 5-year average of $7.6 million and a median of $7.6 million in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases soared 188.45% in 2022 and declined 25.67% in 2024, its largest moves.
• Tracing KRYS's Operating Leases over 5 years: stood at $7.4 million in 2022, then slipped by 10.2% to $6.6 million in 2023, then declined by 8.7% to $6.0 million in 2024, then grew by 25.22% to $7.6 million in 2025, then retreated by 3.38% to $7.3 million in 2026.
• Business Quant data shows KRYS's Operating Leases at $7.3 million in Q1 2026, $7.6 million in Q4 2025, and $7.8 million in Q3 2025.